ClinicalTrials.gg
RecruitingNCT07545395Updated Apr 22, 2026

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

A Phase 3 interventional study of KN057 in Hemophilia A or B, sponsored by Suzhou Alphamab Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Suzhou Alphamab Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
28th of 80
70 · median 54
Started
2026
with 8 others
Phase 3
41 of 93
9 open now
Primary completion
2027-12
later than 25 of 38 live
Registered
89th of 93
by date

Among the 93 studies in Hemophilia A with a site in China, this one is the 28th largest by planned enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2026, is one of 41 in phase 3, reaches primary completion later than 25 of the 38 other live ones, and was the 89th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

The purposes of this open-label, multicenter III clinical trial are to evaluate the safety and efficacy of long-term preventive treatment with KN057 in Haemophilia A or B patients with or without inhibitors, and to assess the pharmacokinetic characteristics of the new and old processes KN057.

The participants in Part PK will be randomly assigned to Old process Group or New process Group in a 1:1 ratio. The participants in Old process Group will receive old process KN057 prophylaxis for the first 26 weeks and new process KN057 prophylaxis for the following 26 weeks. The participants in New process Group will receive new process KN057 prophylaxis for both the first 26 weeks and the last 26 weeks.

The participants in Part non-PK will be non-randomized and treated with new process KN057 for 52 weeks prophylaxis after enrollment.

Priority screening and enrollment of participants who have participated in the KN057-A-301 or KN057-A-302 study.

03

Conditions studied

  • Hemophilia A or B

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, 12 to 65 years old at the time of signing , body weight ≥30 kg and \<28 kg/m\^2 at screening.
  2. For participates with inhibitors: Tested positive for high-titer FVIII or FIX inhibitors (≥ 5 BU/mL) at screening; or tested positive for low-titer FVIII or FIX inhibitors (0.6 BU/mL or [ULN] \< inhibitor titer \< 5 BU/mL) at screening, with ongoing treatment using bypassing agents (rFVIIa or PCC).

    For participates without inhibitors: Severe and moderately severe hemophilia A or hemophilia B (FVIII or FIX activity level ≤2%); FVIII or FIX inhibitor test is negative (\<0.6 BU/ml) or lower than the lower limit of laboratory normal values during the screening period; There is no history of FVIII or FIX inhibitors in the past, or there has been an inhibitor, but the inhibitor has turned negative for at least 5 years before screening and has not reappeared (no positive inhibitor was detected); Use coagulation factor replacement therapy for no less than 100 exposure days before screening.

  3. Participates with inhibitors agree to avoid using PCC for treatment when breakthrough bleeding occurred. Participates without inhibitors agree to be treated with standard half-life coagulation factors (FVIII or FIX) in the event of breakthrough bleeding.

Exclusion criteria

Exclusion Criteria:

  1. Have serious or poorly controlled chronic diseases or obvious systemic diseases.
  2. Have a history of thromboembolic disease, or currently have symptoms or signs related to thromboembolic disease or being treated with thrombolytic/antithrombotic therapy.
  3. Have high-risk factors for thrombosis: such as atrial fibrillation, atherosclerotic diseases of important arteries, ischemic disease of important organs, vascular occlusive disease, diseases with a high risk of thrombosis, or indwelling central venous catheter.
  4. Known or suspected to any constituent of the trial product or related products.
  5. Have undergone major surgery (as determined by the investigator) within 3 months before screening, or have elective surgery planned during the study.
  6. Used Emicizumab treatment within 6 months before screening.
  7. Have received any gene therapy for hemophilia in the past.
  8. Other factors that the investigator deems inappropriate for participating in this trial, such as the presence of concomitant diseases, treatment or examination abnormalities that affect the subject's safety during the trial or affect the interpretation of trial results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Part PK # Old process Group

    The participants in Old process Group will receive old process KN057 prophylaxis for the first 26 weeks and new process KN057 prophylaxis for the following 26 weeks.

    Drug: KN057

  • Experimental
    Part PK # New process Group

    The participants in New process Group will receive new process KN057 prophylaxis for both the first 26 weeks and the last 26 weeks.

    Drug: KN057

  • Experimental
    Part non-PK

    The participants in Part non-PK will be treated with new process KN057 for 52 weeks prophylaxis after enrollment.

    Drug: KN057

Interventions

  • DrugKN057

    KN057 will be administered subcutaneously once a week.

06

What researchers measure

Primary outcomes

  1. Incidence of TEAE.

    TEAE refers to 'treatment emergent adverse event'.

    Time frame: Up to 12/26/56 weeks.

  2. Incidence of TEAE related to the experimental drug.

    Time frame: Up to 12/26/56 weeks.

  3. Incidence of SAE.

    SAE refers to 'serious adverse event'.

    Time frame: Up to 12/26/56 weeks.

  4. Incidence of thromboembolic events.

    Time frame: Up to 12/26/56 weeks.

  5. Incidence of TMA and DIC.

    TMA refers to 'thrombotic microangiopathy'. DIC refers to 'disseminated intravascular coagulation'.

    Time frame: Up to 12/26/56 weeks.

  6. Incidence of hypersensitivity type reactions.

    Time frame: Up 12/26/56 weeks.

  7. Incidence of injection site reactions.

    Time frame: Up to 12/26/56 weeks.

  8. Incidence of clinically significant laboratory value abnormalities.

    Time frame: Up to 12/26/56 weeks.

  9. Number of participants with clinically significant changes from baseline in electrocardiograms.

    Time frame: Up to 12/26/56 weeks.

  10. Number of participants with clinically significant changes from baseline in vital signs.

    Time frame: Up to 12/26/56 weeks.

  11. Number of participants with clinically significant changes from baseline in physical exam.

    Time frame: Up to 12/26/56 weeks.

Secondary outcomes

  1. The exposure levels of KN057 after the first administration in both the new and old processes.

    Time frame: Up to 12 weeks.

  2. The steady-state trough concentrations of KN057 after the first administration in both the new and old processes.

    Time frame: Up to 12 weeks.

  3. Incidence of anti-KN057 antibody (ADA) and neutralizing antibody (Nab).

    immunogenicity

    Time frame: Up to 12/26/56 weeks.

  4. Annualized bleeding rate (ABR) calculated based on treated spontaneous and traumatic bleeding episodes.

    Time frame: Up to 26/52 weeks.

  5. ABR calculated based on bleeding episodes, treated spontaneous bleeding episodes, treated joint bleeding episodes.

    Time frame: Up to 26/52 weeks.

  6. The correlation between the steady-state trough concentrations of KN057 and the incidence of TEAE related to the experimental drug.

    Time frame: Up to 26 weeks.

  7. The correlation between the steady-state trough concentrations of KN057 and ABR calculated based on treated spontaneous and traumatic bleeding episodes.

    Time frame: Up to 26 weeks.

  8. Levels of Free TFPI.

    pharmacodynamics

    Time frame: Up to 12/26/56 weeks.

  9. Change from baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L).

    The EQ-5D-5L questionnaire is made up for 2 components, health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; every dimension contains 5 levels (5L): no difficulty, a little difficulty, moderate difficulty, severe difficulty, very severe difficulty/inability to perform. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: Up to 26/52 weeks.

  10. The annual usage of on-demand treatment drugs (adjusted by body weight).

    Time frame: Up to 26/52 weeks.

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 300020, China
    Recruiting
    • Renchi Yang, Doctor · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 21 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2026
First posted
Apr 22, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07545395
Lead sponsor
Suzhou Alphamab Co., Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Mar 13, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Yanrong Dong, Master
Contact
yanrongdong@alphamab.com
+86 18914005458
Renchi Yang, Doctor
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Hu Zhou, Doctor
principal investigator · Henan Cancer Hospital
Changcheng Zheng, Doctor
principal investigator · The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Xielan Zhao
principal investigator · Xiangya Hospital of Central South University
Hongbo Cheng, Doctor
principal investigator · Jiangxi Provincial People's Hopital
Yanping Song, Doctor
principal investigator · Xi'an Central Hospital
Zeping Zhou, Doctor
principal investigator · The Second Affiliated Hospital of Kunming Medical University
Jie Yin, Doctor
principal investigator · The First Affiliated Hospital of Soochow University
Zhenyu Yan, Doctor
principal investigator · North China University of Science and Technology
Yun Chen, Doctor
principal investigator · Jinan Central Hospital
Yinsuo Zheng, Doctor
principal investigator · Bao Ji Central Hospital
Shu Chen, Doctor
principal investigator · The Second Affiliated Hospital of Chongqing Medical University
Ying Dong, Doctor
principal investigator · Maoming City People's Hospital
Xiaoli Wu, Doctor
principal investigator · The Second Hospital of Hebei Medical Hospital
Yanming Zhang, Doctor
principal investigator · Huai'an Second People'Hospital
Miaoyong Zhu, Doctor
principal investigator · Wenzhou People's Hospital
Haiping Yang, Doctor
principal investigator · The First Affiliated Hospital of Henan University of Science and Technology
Qingyi Wang, Doctor
principal investigator · The Fifth Affiliated Hospital of Anhui Medical
Wenqian Li, Doctor
principal investigator · Qinghai People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KN057

Start the discussion